Regardless, there is clearly a need for targeted therapies for GemA that can delay or prevent progression HA-1077 supplier to GBM. However, until now there has been no useful animal model of GemA available to test adjuvant therapy after surgical debulking as humans are treated. Furthermore, the murine models of glioma have not been predictive of toxicity or

efficacy in humans, and this has undoubtedly contributed to the painstakingly slow progress in therapeutic development. Similarly to humans, dogs develop spontaneous brain tumors that often carry a dismal prognosis. Based on an incidence of primary brain tumors in dogs of 20 per 100,000/year, it has been estimated that 12,000 dogs could be eligible for recruitment into clinical studies in the United States annually [5]. We and others have found many similarities between human and canine glioma such as: overexpression of the epidermal growth factor receptor, mutation of the Tp53 tumor suppressor gene [6], extensive invasion into normal brain, peritumoral edema and necrosis [7] and [8], hemorrhage, compression, herniation, and obstructive hydrocephalus AZD6244 cost [9], [10] and [11]. Similar to humans, the prognosis for dogs with brain tumors is poor regardless of therapeutic intervention. However, much less is known about treatment outcomes

because of a historical lack of treatment options in dogs and because only a small number of studies, each of which includes few dogs, have been reported. The median survival time for dogs with glioma (any grade) that do not receive any type of treatment ranges between 6 and 13 days [9] and [10]. In dogs receiving only palliative

therapy the range is 60–80 days [12] and [13]. Radiation therapy may have resulted in an increased survival time in one dog with glioma (176 days) as below compared to corticosteroid therapy in three dogs with glioma (18, 40 and 64 days) [12]. The median survival for 9 dogs putatively diagnosed with glioma at our institution based on imaging characteristics of an intra-axial mass was 29 days (range 1–128 days). These dogs did not receive any therapy other than corticosteroids and anticonvulsants. The clinical similarities between dogs and humans suggest that dogs may represent an outstanding model for testing targeted therapies; both dogs and humans might benefit from these studies. We previously developed a dendritic cell culture-free vaccine consisting of glioma cell lysate and CpG ODN, “CpG/Lysate”, that significantly extended survival of glioma-bearing mice [14]. CpG ODN is a potent vaccine adjuvant that signals through toll like receptor nine (TLR9) in dendritic cells and B cells to induce adaptive anti-tumor immune response in murine models and select cancer patients (reviewed in [15]).